While the Trump administration is pushing to accelerate clinical AI adoption, SCAI has emphasized that physicians must guide how the technology is implemented and governed.

The new device, which provides users with real-time images in full color, is now approved by the FDA to be used in the peripheral vasculature. Meanwhile, first-in-human data published in Stroke explored its potential in the cerebral vasculature. 

Researchers noted that these requirements are more common for Black and Hispanic patients, creating a critical barrier to guideline-recommended care.

The randomized COBRRA trial included more than 2,700 patients with acute symptomatic pulmonary embolism or proximal deep-vein thrombosis. 

When working-age adults develop cardiovascular disease, it often ends up eating up a significant amount of their income. Are insurance companies doing enough to help these patients? 

Vascular surgeons play a critical role in today's evolving healthcare landscape. However, researchers noted, they often do not get the respect or appreciation they deserve.

However, the regular supply of these imaging radiotracers may not be back online for another few months.

The cardiovascular mortality rate in the United States decreased dramatically from 2000 to 2011. Since then, however, it has remained relatively unchanged.

The newly cleared device was built to provide support, trackability and stability during the treatment of time-sensitive stroke patients. 

Researchers explored data from more than 123,000 patients, noting that dozens of the adverse complications included on current labels can safely be removed. 

After years of implanting and studying LAAO devices, an interventional cardiologist with the University of Chicago has designed a new alternative that could reduce the risk of bleeding and save health systems money.

As soon as Esperion Therapeutics gained FDA clearance for Nexletol in 2020, competitors started trying to copy it. The company is fighting back. 

The U.S. Department of Justice said the insurer upcoded patient diagnoses to boost risk-adjusted payments it received from the Centers for Medicare & Medicaid Services. The company did not admit to wrongdoing, despite agreeing to the payout. 

The Columbus, Ohio-based imaging group is repositioning the business to “strengthen brand visibility, clarify service offerings and support long-term growth in an increasingly competitive radiology marketplace.”